Building Blocks

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>2-Hydroxy-[1,1'-biphenyl]-3-carboxylic acid (2HBC) is a monomer that belongs to the group of ester compounds. It has been shown to inhibit the growth of trichophyton mentagrophytes and other fungi by forming hydrogen bonds with the enzyme activities in the cell wall. 2HBC also inhibits microbial growth by binding to enzymes such as phospholipase A2, cyclooxygenase, and lipoxygenase, which are involved in inflammatory processes. This drug also inhibits bacterial growth by binding to the ribosome, preventing protein synthesis and leading to cell death. The inhibition of microbial growth is not limited to bacteria; it also occurs in fungi and protozoa. 2HBC has been shown to be active against both extracellular and intracellular microbial infections.</p>

<p>Versatile small molecule scaffold</p>

<p>Sodium 2-hydroxyethoxyacetate is a cross-linker that is used to immobilize proteins and enzymes. It has been shown to be effective in the treatment of autoimmune diseases, such as rheumatoid arthritis. This chemical can also be used as a cross-linking agent for the production of biodegradable polymers. The synthesis of this chemical was first reported in 1874 and it has been used for copolymerization with other compounds to form particles with potential biomedical applications.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>2,4-Dimethoxyphenyl isothiocyanate (DMITC) is a molecule that has been shown to have pro-apoptotic activity against human colorectal carcinoma cells. It also inhibits the growth of the colon cancer cells by inducing apoptosis. DMITC has been shown to inhibit the synthesis of DNA and RNA in a dose-dependent manner. This molecule is efficiently synthesized by reacting an imine with an isothiocyanate. DMITC has cytometric analysis for mechanistic studies and can be used as a chemotherapeutic agent for cancer treatment.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>2-Ethynyl-4-methylthiazole is a cell-based kinase inhibitor that binds to the ATP binding site on the enzyme and inhibits phosphorylation. It was shown to inhibit cell growth in vitro by interfering with the production of TGF-β, activin, and other growth factors. The inhibitory activity of 2-Ethynyl-4-methylthiazole is selective for receptor kinases and is not effective against alk5 kinase. This drug has been shown to be an inhibitor of cellular growth in vitro and may be useful for the treatment of cancer.</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>Versatile small molecule scaffold</p>

<p>2-Cyano-5-fluorophenol is an organic compound that is used as a precursor to medicines and other chemicals. It reacts with calcium hydroxide in water to form 2-cyano-5-hydroxyfluorobenzene, which can be hydrolyzed to form 2-cyano-5-chlorofluorobenzene. This compound can also react with sodium hydroxide to produce sodium cyanate, which can be hydrolyzed to form sodium chloride and hydrogen cyanide gas. The alkali metal ions are needed for this reaction, which is why the product should not be exposed to water or moisture. 2-Cyano-5-fluorophenol has been shown to have liquid crystal properties and is used in the production of certain types of polymers. 2Cyano-5Fluorophenol crystals are also used in some medicines such as acetaminophen (paracetamol).</p>

<p>Versatile small molecule scaffold</p>

<p>2-Bromo-3,3,3-trifluoro-1-propene is a chemical compound that has been synthesized in an asymmetric reaction. The reactant is bromopropane and the product is 2,2,2-trifluoropropene. The methylene group on the propene molecule is activated by the nucleophilic attack of a fluoride ion from hydrogen fluoride to form a cavity with a highly strained bond. The kinetic study of this reaction revealed that the activation energy for the reaction is 42 kJ/mol. Palladium-catalyzed coupling reactions are catalyzed by palladium and require nonpolar solvents such as toluene or dichloromethane. This type of reaction has been shown to be exothermic with an isolated yield of 1%.</p>

<p>Tri-GalNAc-NHS ester is a multivalent molecule composed of three GalNAc cluster arms. It is a protein degrader and a ligand of the asialoglycoprotein receptor (ASGPR) used for the development of targeted therapies for liver diseases. The GalNAc arms enable high-affinity binding to the ASGPR on hepatocyte surfaces. The crucial functional group, N-hydroxysuccinimide (NHS) ester, is known for its ease of conjugation with various biomolecules possessing amine (NH2) groups. This biocompatible reaction strategy allows the design and development of targeted conjugates such as drug-GalNAc conjugates, siRNA delivery vehicles, or probes for ASGPR imaging in the liver.</p>